Day 1

09:00 Registration and refreshments

09:30 Opening address from chair

Richard Lawrence
OTC Business Line Manger for Consumer Health
IMS Health

09:40 Anti-Nicotine addiction vaccines, a new class of smoking cessation therapies

• Nicotine addiction and inadequacy of current therapies for long term abstinence

• Advantages of anti-nicotine addiction vaccine therapies for long term smoking cessation

• NicVAX development update and advantages

Dr Raafat Fahim
Chief Executive Officer
Nabi Biopharmaceuticals

10:20 Analysing the existing market opportunities for new anti-smoking aids

• Examining the key trends among the smoking cessation market

• Identifying the market drivers to produce innovated solutions

• Prescribing and pricing of OTC market up dates

• Exploring the role of NRT and their future developments

Richard Lawrence
OTC Business Line Manger for Consumer Health
IMS Health

11:00 Morning refreshments

11:20 Lung Cancer in the 21st Century

• Analysing the changing histology of lung cancer

• Reviewing smoking/genes and lung cancer

• Deprivation of lung cancer associated with smoking and models of lung cancer care

• Examining mortality in the near future and throughout the first half of the 21st century could be substantially reduced by current smokers giving up the habit

Dr Martin Ledson
Consultant Chest Physician
Liverpool Heart and Chest Hospital

12:00 Smokers response to stopping and relapsing

• Exploring cancer patients choices of quitting smoking- Do they believe it is worth it

• Discovering the support available to cancer patients within smoking cessation and NRT

• Examining statistical outcomes of smoking cessation and cancer patience within the LHCH Service

Trish Jones
Smoking Advisor
Liverpool Heart and Chest Hospital

12:40 Networking Lunch

13:40 Scientific study of Nicotine vaccine in clinical development

Lena Degling Wikingsson
CEO
Independent Pharmaceutica

14:20 British Heart Foundation- Innovative ways of reaching ethnic minorities

• Development of innovated smoking cessation campaign for ethnic minorities

• Analysing why we need to take different approaches to reach ethnic communities

• Examining why the need to target certain ethnic minority group

• Discovering the pioneering research, and support and care for smoking cessation patients

Qaim Zaidi
Ethic Strategy Coordinator
British Heart Foundation

15:00 Afternoon refreshments

15:20 Discovering the effects of cannabis and Nicotine

• Cannabis smoking and periodontal disease among young adults

• Misconception of smoking cannabis-What steps are being taken

• Examining the effects when combining two toxic drugs and the associated diseases

Pushpinder Virdee
Quit *

16:00 Exploring the somatic and psychological effects associated with Nicotine

• Analysing the development of Major depressive disorder associated with smoking

• Examining the continuation that nicotine’s potential for psychological dependency exceeds all other studied drugs

• How smoking aids are helping control the delirium tremens when a smoking addiction had been quit

• Understanding the research interests including neuropsychopharmacological approaches for the treatment of depression, anxiety, cognitive dysfunction linked with smoking dependency

16:40 Closing remarks from the chair

16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

TOP

Day 2

09:00 Registration and refreshments

09.30 Opening address from the chair

Mark Tucker
Chief Executive Officer
G-Nostics

09:40 Smoking cessation and community pharmacy: A Scottish perspective

• Strengths and weakness of the community pharmacy model

• Review of 5 years experience in greater Glasgow & Clyde

• Smoking cessation as a component of the new community pharmacy contract with NHS Scotland

• Managing clients with special needs

• Innovations for future developments

Scott Bryson
Lead Pharmaceutical Public Health
NHS Greater Glasgow & Clyde Pharmacy

10:20 Presentation to be announced

11:00 Morning refreshments

11:20 Analysing the positive effects of Chantix

• Discovering Chanix success compared to other NRT

• The promotion of Chanix within the anti-smoking market

• Exploring Pfizer as important role models within the smoking cessation field

12:00 Strategies for identifying novel biological and behavioural targets for smoking cessation

• Evidence from molecular genetic studies for novel treatment targets

• Cognitive- behavioural interventions for relapse prevention

• Existing and novel pharmacotherapies for smoking cessation

Dr Marcus Munafo
Department of Experimental Psychology
University of Bristol

12:40 Networking lunch

13:40 Using Pharmacogenetics to develop a second generation Nicotine patch for more effective personal treatment

• Establishing the clinical need

• Where is the current technology gap

• What are the current and anticipated regulatory environments for such a companion diagnostic product

• Analysing the commercial implications

Mark Tucker Dr Robert Walton
Chief Executive Officer Department of Clinical Pharmacology
G-Nostics Oxford University

14:20 Analysing smoking cessation within the workforce- The Royal Mail Experience

• Implemented strategies within the blue collar workers and their views

• Examining what NRT are being introduced to contribute to a healthier environment

• Exploring the results and benefits to both employees and employers

Dr Su Wang
Group Head of Health
Royal Mail Group

15:00 Afternoon refreshments

15:20 Examining how 24 hour online support increases NRT and Buprorion compliance

• Optimising effective usage of NRT and Buproprion use among users

• Analysing implemented eHealth care programs

• Examining the success and future development of eHealth care

Trevor Van Mierlo
CEO
V-CC Systems

16:00 Panel Discussion - Future directions in smoking cessation

• Understanding the competitive environment, the market’s major players and leading brands

• Pinpointing growth sectors and trends that identify factors driving change

• Revolutionising technologies and products emerging from medical area research

• Developing the way forward with providing innovative and effective solutions

The panel will be made up of selected presenters from both days

16:30 Chair’s closing remark

16:40 End of conference

TOP